Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Benedito A. Carneiro; Ludimila Cavalcante; Devalingam Mahalingam; Anwaar Saeed; Howard Safran; Wen Wee Ma; Andrew L. Coveler; Steven Powell; Bruno Bastos; Elizabeth Davis; Vaibhav Sahai; William Mikrut; James Longstreth; Sheri Smith; Taylor Weisskittel; Hu Li; Brittany A. Borden; R. Donald Harvey; Solmaz Sahebjam; Andres Cervantes; Austin Koukol; Andrew P. Mazar; Neeltje Steeghs; Razelle Kurzrock; Francis J. Giles; Pamela Munster

doi:10.1158/1078-0432.CCR-23-1916

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L. Coveler, Steven Powell, Bruno Bastos, Elizabeth Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor Weisskittel, Hu Li, Brittany A. Borden, R. Donald Harvey, Solmaz Sahebjam, Andres CervantesAustin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	522-531
Number of pages	10
Journal	Clinical Cancer Research
Volume	30
Issue number	3
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-1916
State	Published - Feb 1 2024
Externally published	Yes

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-23-1916

Cite this

Carneiro, B. A., Cavalcante, L., Mahalingam, D., Saeed, A., Safran, H., Ma, W. W., Coveler, A. L., Powell, S., Bastos, B., Davis, E., Sahai, V., Mikrut, W., Longstreth, J., Smith, S., Weisskittel, T., Li, H., Borden, B. A., Harvey, R. D., Sahebjam, S., ... Munster, P. (2024). Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clinical Cancer Research, 30(3), 522-531. https://doi.org/10.1158/1078-0432.CCR-23-1916

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. / Carneiro, Benedito A.; Cavalcante, Ludimila; Mahalingam, Devalingam et al.
In: Clinical Cancer Research, Vol. 30, No. 3, 01.02.2024, p. 522-531.

Research output: Contribution to journal › Article › peer-review

Carneiro, BA, Cavalcante, L, Mahalingam, D, Saeed, A, Safran, H, Ma, WW, Coveler, AL, Powell, S, Bastos, B, Davis, E, Sahai, V, Mikrut, W, Longstreth, J, Smith, S, Weisskittel, T, Li, H, Borden, BA, Harvey, RD, Sahebjam, S, Cervantes, A, Koukol, A, Mazar, AP, Steeghs, N, Kurzrock, R, Giles, FJ & Munster, P 2024, 'Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies', Clinical Cancer Research, vol. 30, no. 3, pp. 522-531. https://doi.org/10.1158/1078-0432.CCR-23-1916

@article{89e446a7f7d54782b47fbd5771a41c92,

title = "Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies",

author = "Carneiro, {Benedito A.} and Ludimila Cavalcante and Devalingam Mahalingam and Anwaar Saeed and Howard Safran and Ma, {Wen Wee} and Coveler, {Andrew L.} and Steven Powell and Bruno Bastos and Elizabeth Davis and Vaibhav Sahai and William Mikrut and James Longstreth and Sheri Smith and Taylor Weisskittel and Hu Li and Borden, {Brittany A.} and Harvey, {R. Donald} and Solmaz Sahebjam and Andres Cervantes and Austin Koukol and Mazar, {Andrew P.} and Neeltje Steeghs and Razelle Kurzrock and Giles, {Francis J.} and Pamela Munster",

note = "Publisher Copyright: {\textcopyright}2023 American Association for Cancer Research.",

year = "2024",

month = feb,

day = "1",

doi = "10.1158/1078-0432.CCR-23-1916",

language = "English",

volume = "30",

pages = "522--531",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "3",

}

TY - JOUR

T1 - Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

AU - Carneiro, Benedito A.

AU - Cavalcante, Ludimila

AU - Mahalingam, Devalingam

AU - Saeed, Anwaar

AU - Safran, Howard

AU - Ma, Wen Wee

AU - Coveler, Andrew L.

AU - Powell, Steven

AU - Bastos, Bruno

AU - Davis, Elizabeth

AU - Sahai, Vaibhav

AU - Mikrut, William

AU - Longstreth, James

AU - Smith, Sheri

AU - Weisskittel, Taylor

AU - Li, Hu

AU - Borden, Brittany A.

AU - Harvey, R. Donald

AU - Sahebjam, Solmaz

AU - Cervantes, Andres

AU - Koukol, Austin

AU - Mazar, Andrew P.

AU - Steeghs, Neeltje

AU - Kurzrock, Razelle

AU - Giles, Francis J.

AU - Munster, Pamela

PY - 2024/2/1

Y1 - 2024/2/1

UR - http://www.scopus.com/inward/record.url?scp=85184146802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85184146802&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-1916

DO - 10.1158/1078-0432.CCR-23-1916

M3 - Article

C2 - 37982822

AN - SCOPUS:85184146802

SN - 1078-0432

VL - 30

SP - 522

EP - 531

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 3

ER -

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this